Back to today’s briefing

Story perspectives

High Cost of Weight Loss Drugs Sparks Policy Debate

3/21/2025

24 3

Summary

Story summary

A recent study in JAMA Health Forum reveals that while weight loss drugs Wegovy and Zepbound show clinical effectiveness, their high prices make them unaffordable for many. With limited insurance coverage worsening obesity disparities, expanding Medicare could cost an additional $35 billion, underscoring the urgent need for policy changes to enhance access to these vital treatments.

1 of 1

Story summary

A recent study in JAMA Health Forum reveals that while weight loss drugs Wegovy and Zepbound show clinical effectiveness, their high prices make them unaffordable for many. With limited insurance coverage worsening obesity disparities, expanding Medicare could cost an additional $35 billion, underscoring the urgent need for policy changes to enhance access to these vital treatments.